Filing Flows › Interpace Biosciences (IDXG) › Q2 2026 › vs Q1 2026
Interpace Biosciences (IDXG) Q2 2026 vs Q1 2026 (quarter over quarter)
Interpace Biosciences's revenue rose $99K (+1%) from $9.0M in Q1 2026 to $9.1M in Q2 2026. Gross margin 61.9% against 65.4% (-3.5 pts).
Interpace Biosciences, Q2 2026: revenue $9.1M (-1% year over year), operating margin 3.5%, net earnings $158K, operating cash flow $98K. The chart draws each line against Q1 2026, the increases inside each band.
Margins
| Q2 2026 | Q1 2026 | Change | |
|---|---|---|---|
| Gross margin | 61.9% | 65.4% | -3.5 pts |
| Operating margin | 3.5% | 12.4% | -8.9 pts |
| Net margin | 1.7% | 8.0% | -6.3 pts |
| Free cash flow margin | 0.4% | 1.6% | -1.1 pts |
Every line
| Line | Q2 2026 | Q1 2026 | Change | % |
|---|---|---|---|---|
| Revenue | $9.1M | $9.0M | $99K | +1% |
| Gross profit | $5.7M | $5.9M | −$251K | -4% |
| Cost of revenue | $3.5M | $3.1M | $350K | +11% |
| Operating profit | $321K | $1.1M | −$802K | -71% |
| Operating expenses | $5.3M | $4.8M | $551K | +12% |
| Pre-tax earnings | $222K | $1.0M | −$801K | -78% |
| Other expense, net | $99K | $100K | −$1K | -1% |
| Research & development | $149K | $153K | −$4K | -3% |
| Sales & marketing | $2.2M | $2.2M | $30K | +1% |
| General & admin | $3.0M | $2.5M | $525K | +21% |
| Net earnings | $158K | $721K | −$563K | -78% |
| Income tax | $64K | $302K | −$238K | -79% |
| Operating cash sources | $289K | $843K | −$554K | -66% |
| Depreciation & amortization | $127K | $118K | $9K | +8% |
| Share-based compensation | $4K | $4K | $0 | 0% |
| Working capital & other | $191K | $560K | −$369K | -66% |
| Operating cash flow | $98K | $283K | −$185K | -65% |
| Free cash flow (OCF − capex) | $41K | $142K | −$101K | -71% |
| Capital expenditures | $57K | $141K | −$84K | -60% |
Questions
How much did Interpace Biosciences's revenue grow quarter over quarter in Q2 2026?
Interpace Biosciences's revenue rose $99K (+1%) from $9.0M in Q1 2026 to $9.1M in Q2 2026. Gross margin 61.9% against 65.4% (-3.5 pts).